Mostrando 10 resultados de: 11
Filtros aplicados
Subtipo de publicación
Article(11)
Publisher
BMC Cancer(1)
BMC Infectious Diseases(1)
BMC Pharmacology and Toxicology(1)
Biotecnologia Aplicada(1)
British Journal of Cancer(1)
C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells
ArticleAbstract: For decades Experimental Autoimmune Encephalitis (EAE) has remained as an unsurpassed multiple sclerPalabras claves:Central nervous system, Demyelination, Multiple Sclerosis, Neurodegenerative disorder, Regulatory T cellsAutores:Acosta-Medina E.F., Alexey Llópiz-Arzuaga, Alonso-Ramírez R., Cervantes-Llanos M., Falcón-Cama V., Guillén-Nieto G.E., Lagumersindez-Denis N., López-Saura P.A., Marín-Prida J., Martínez-Sánchez G., Pentón-Arias E., Pentón-Rol G., Rodríguez-Jiménez E., Valenzuela-Silva C.M.Fuentes:googlescopusCIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
ArticleAbstract: Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, wPalabras claves:apoptosis, Cancer targeted therapy, Casein kinase 2Autores:Acevedo B.E., Alonso D.F., Ariosa J., Bacardí D.M., Baladron I., Besada-Pérez V., Betancourt L., Castellanos L.R., Cosme K., Cruz M., Díaz A., Falcón-Cama V., Farina H., Garay H.E., Gil J., Gómez D., Gómez R., González L.J., Hernández I., Herrera L., López C., López-Mola E., López-Saura P.A., Marcelo J.L., Mendoza O., Perea-Rodríguez S.E., Perera Y., Puchades Y., Reyes O., Rodriguez A., Sánchez A., Santana A., Serrano J.M., Sigman H., Silva R., Solares M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopusAdjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study
ArticleAbstract: Background: High antibiotic resistance is described in atypical Mycobacteriosis, mainly by MycobactePalabras claves:Autores:Bello-Rivero I., Fernández-Olivera N., García-García I., González-Méndez L., Jiménez-Madrigal G., López-Saura P.A., Martínez-Sánchez G., Milanés-Virelles M.T., Rodríguez-Acosta C., Sánchez-de la Osa R.B., Santos-Herrera Y., Thelvia I. Ramos Gómez, Valdés-Quintana M., Valenzuela-Silva C.M.Fuentes:googlescopusOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
ArticleAbstract: Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injectiPalabras claves:B23/nucleophosmin, Cervical Cancer, CIGB-300, tumour uptakeAutores:Acevedo B.E., Alonso D.F., Ancízar J.A., Baladron I., Casacó C.A., Coca M.A., García I., Gómez R., González L.J., González Y.M., Hernández I., I. Howland-Álvarez, López-Saura P.A., Martínez Y.M., Molina L., Perea-Rodríguez S.E., Perera A., Perera Y., Prats A., Reyes V., Solares M., Torres L.A., Valenzuela-Silva C.M.Fuentes:scopusIntegrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody
ArticleAbstract: The multiple-dose strategy with the monoclonal ior EGF/r3 antibody, in xenograft bearing nude mice,Palabras claves:Allometric scaling, Dosage regimen, Integrated pharmacokinetic-pharmacodynamic, Monoclonal antibody ior EGF/r3, Survival time, Tumor growth delayAutores:Alonso K., Alvarez D., Beausoleil I., Bécquer M.d.l.A., Castillo R., Duconge J., Fernández-Sánchez E.M., Matheu J., Tania Crombet, Valenzuela-Silva C.M., Vecino G.Fuentes:scopusPharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
ArticleAbstract: Background: More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. TPalabras claves:2'-5' oligoadenylate synthetase, Beta2-microglobulin, interferons, Neopterin, pharmacodynamics, pharmacokineticsAutores:Bello-Rivero I., Campos-Mojena R., Cruz-Ramírez A., Díaz-Machado A., García-Vega Y., González-Delgado C.A., Hernández-González I., I. Howland-Álvarez, López-Saura P.A., Martín-Trujillo A., Pérez-Rodríguez S., Santana-Milián H., Tuero-Iglesias Á.D., Valenzuela-Silva C.M.Fuentes:scopusTreatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusSafety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
ArticleAbstract: Background: SOBERANA 02 has been evaluated in phase I and IIa studies comparing homologous versus hePalabras claves:Conjugate vaccine, covid-19, heterologous schedule, phase IIb clinical trial, recombinant RBD, Translation to patientsAutores:Acevedo-Martínez Y., Acosta-Martinez M.A., Alfaro-Guzmán A., Amoroto M., Arteaga-García A., Ávila-Cabreja J.A., Baro-Roman G., Bergado-Baez G., Biglari A., Boggiano-Ayo T., Brito-Pascual I., Cardoso-SanJorge F., Chen G.W., Climent-Ruiz Y., Coviella-Artime J.M., Cruz-Sui O., Cubas-Curbelo M., Díaz-Hernández M., Domínguez-Pentón Y.R., Doroud D., Dubed-Echevarría M., Enriquez-Puertas J., Espi-Ávila J., Espino-Rojas N.T., Estoque-Cabrera S., Fernández-Castillo S., Fontanies-Fernández M., Galano-Frutos E., Garcés-Hechavarría A., García-Carmenate M., García-López E., García-Montero M., García-Rivera D., García-Vega Y., Garrido-Arteaga R., Gómez-Maceo Y., González-Mugica R., Guillén-Obregón B., Hernández-Garcia T., Lora-García J., Martínez-Bedoya D., Martínez-Pérez M., Martínez-Rivera R., Medina-Nápoles M., Medinas-Santos G.M., Mendoza-Hernández I., Misladys Rodríguez Ortega, Morales-Ruano S., Morffi-Cinta I., Muñoz Y., Noa-Romero E., Ojito-Magaz E., Ontivero-Pino I., Orosa-Vázquez I., Palenzuela-Diaz A., Paredes-Moreno B., Pérez-Guevara M.T., Perez-Perez A., Pérez-Rodríguez S., Pi-Estopiñán F., Quintero-Moreno L., Ramírez-Gonzalez U., Reyes-Matienzo R., Rivera D.G., Rodríguez-Castillo P.G., Rodriguez-González M., Rodríguez-Noda L., Sanchez-Ramirez B., Santana-Mederos D., Santos-Vega B.L., Sarda-Rodriguez I.L., Toledo-Romani M.E., Valdes-Balbín Y., Valenzuela-Silva C.M., Valera-Fernández R., Verdecia-Sánchez L., Verez-Bencomo V., Zulueta-Pérez L.Fuentes:scopusSafety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
ArticleAbstract: Background: Cervical cancer is now considered the second leading cause of death among women worldwidPalabras claves:Autores:Acevedo B.E., Alonso D.F., Baladron I., Castillo D., Díaz A., Gómez R., González C.A., Herrera L., López-Saura P.A., Perea-Rodríguez S.E., Santana A., Sigman H., Solares A.M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopusRecombinant gamma interferon for the treatment of pulmonary and mycobacterial diseases
ArticleAbstract: An increased antibiotic resistance is described for Mycobacterium tuberculosis and atypical mycobactPalabras claves:BCG, Idiopathic pulmonary fibrosis, Interferon gamma, Lymphadenitis, Multidrug-resistant pulmonary tuberculosis, Mycobacteria, Mycobacterium avium complexAutores:Abreu G., Cayón I., García I., González-Méndez L., Jiménez G., López P., Milanés M.T., Sánchez R.B., Santos Y., Thelvia I. Ramos Gómez, Valdés M., Valenzuela-Silva C.M.Fuentes:googlescopus